Aquipta Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Atogepant

Indications/Uses

Prophylaxis of migraine in adults who have at least 4 migraine days/mth.

Click to view Aquipta detailed prescribing information

Dosage/Direction for Use

Recommended dose: 60 mg once daily. Concomitant use w/ strong CYP3A4 & organic anion transporting polypeptide (OATP) inhibitors 10 mg once daily. Severe renal impairment (CrCl 15-29 mL/min) & ESRD (CrCl <15 mL/min) 10 mg once daily.

Click to view Aquipta detailed prescribing information

Overdosage

View Aquipta overdosage for action to be taken in the event of an overdose.

Administration

May be taken with or without food.

Contraindications

Hypersensitivity.

Click to view Aquipta detailed prescribing information

Special Precautions

Reported hypersensitivity reactions, including anaphylaxis, dyspnea, rash, pruritus, urticaria, & facial edema; discontinue use & institute appropriate therapy if a hypersensitivity reaction occurs. May cause somnolence; exercise caution before driving or using machinery. Should preferably be taken after dialysis for patients w/ ESRD undergoing intermittent dialysis. Avoid use & not recommended in patients w/ severe hepatic impairment (Child-Pugh Class C). Not recommended during pregnancy & in women of childbearing potential not using contraception. Lactation; consider developmental & health benefits of breastfeeding along w/ the mother's clinical need for Aquipta & any potential adverse effects on the breastfed infant from Aquipta & the underlying maternal condition. Safety & effectiveness have not been established in ped patients.

Click to view Aquipta detailed prescribing information

Use In Pregnancy & Lactation

Click to view Aquipta detailed prescribing information

Adverse Reactions

Decreased appetite; nausea, constipation; fatigue/somnolence.

Click to view Aquipta detailed prescribing information

Drug Interactions

Significant increased exposure w/ strong CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin) & OATP inhibitors (eg, rifampicin, cyclosporine).

Click to view Aquipta detailed prescribing information

Storage

View Aquipta storage conditions for details to ensure optimal shelf-life.

Description

View Aquipta description for details of the chemical structure and excipients (inactive components).

Action

View Aquipta mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Antimigraine Preparations

ATC Classification

N02CD07 - atogepant ; Belongs to the class of calcitonin gene-related peptide (CGRP) antagonists preparations. Used to relieve migraine.

Regulatory Classification

POM

Presentation/Packing

Form

Aquipta tab 10 mg

Packing/Price

28's

Form

Aquipta tab 60 mg

Packing/Price

28's

Aquipta

Manufacturer:

AbbVie